H.C. Wainwright analyst Joseph Pantginis raised the price target on Viking Therapeutic (NASDAQ: VKTX) to a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change Momentum Movers Trader Talk

Viking Therapeutics (VKTX) Announces Proposed Common Share OfferingSeptember 19, 2018 4:23 PM Viking Therapeutic (VKTX) PT Raised to $28 at SunTrust Robinson HumphreySeptember 18, 2018 3:39 PM Viking Therapeutic (VKTX) PT Raised to $28 at Maxim Group, Matching 'Street High'September 18, 2018 12:31 PM Pre-Open Movers 09/18: (VKTX) (NXEO) (TLRY) Higher; (MDGL) (ATHN) (CBRL) Lower (more...)September 18, 2018 9:24 AM Viking Therapeutics (VKTX): VK2809 Phase II Data Tops Madrigal's MGL-3196 - SunTrustSeptember 18, 2018 8:33 AM Wall Street bounces back as investors shrug off trade tensionsSeptember 18, 2018 7:41 AM Viking Therapeutics (VKTX) Climbs 140% After Shares Resume TradingSeptember 18, 2018 7:37 AM Viking Therapeutics (VKTX) to Resume Trading at 7:35 am ETSeptember 18, 2018 7:17 AM Form 8-K Viking Therapeutics, For: Sep 18September 18, 2018 7:11 AM Viking Therapeutics (VKTX) Says Phase 2 Study of VK2809 in Patients with NAFLD and Elevated LDL-Cholesterol Achieved its Primary EndpointSeptember 18, 2018 7:08 AM Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-CholesterolSeptember 18, 2018 7:05 AM